Research Studies

2017 Research Studies

  • A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis.
    • The purpose of this study is to determine whether the use of the study drug, secukinumab, can help treat patients who have non-radiographic ankylosing spondylitis.  This study is currently actively enrolling.  Further information is available at
    • Physicians and patients are welcome to contact us for more information.
    • The principal investigator, Dr. Michael Bubb, can be reached at the rheumatology office, 352.294.8202.